在不列颠哥伦比亚的首演呼吁改革其昂贵的罕见疾病药物方案五个月之后,没有发生任何变化,使患者无法可靠地获得治疗。 Five months after BC's premier called for reforms to its costly rare disease drug program, no changes have been made, leaving patients without reliable access.

在不列颠哥伦比亚省省长呼吁改革其高成本罕见病药物项目五个月后，至今仍未做出任何具体变化。 Five months after British Columbia’s premier called for reforms to its high-cost rare disease drug program, no concrete changes have been made. 该方案旨在提供救生治疗,但继续面临延误、批准不一致和透明度有限的问题。 The program, intended to provide life-saving treatments, continues to face delays, inconsistent approvals, and limited transparency. 患者和倡导者报告说,尽管有一些临时解决办法,但患者和倡导者在获取和支付能力方面仍面临困难。 Patients and advocates report ongoing struggles with access and affordability, despite some temporary solutions. 卫生官员承认在平衡成本和护理方面存在挑战,但尚未公布改革时间表,使家庭处于不确定状态。 Health officials acknowledge challenges in balancing cost and care but have not announced a timeline for reforms, leaving families in uncertainty.